{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:44:16Z","timestamp":1784641456183,"version":"3.55.0"},"reference-count":31,"publisher":"BMJ","issue":"20","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2018,3,15]]},"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>In statin-treated patients with stable coronary artery disease (CAD), residual risk of cardiovascular events is partly explained by plasma levels of low-density lipoprotein cholesterol (LDL-C). This study aimed to estimate individual benefit of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition in CAD patients already treated with high-dose statin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Individual lifetime benefit was estimated in months gain free of stroke or myocardial infarction (MI) until age 80 years. Predictions were based on two competing risk models developed in data from 4853 patients with CAD originating from the atorvastatin 80\u2009mg arm of the Treating to New Targets (TNT) trial. The relative effect of PCSK9 inhibition was added to the models and was assumed based on average estimates from large clinical trials. We accounted for individual LDL-C levels, assuming 50% LDL-C reduction by PCSK9 inhibition and 21% cardiovascular risk reduction per mmol\/L (39\u2009mg\/dL) LDL-C lowering.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Estimated individual gain was &lt;6 months in 61% of the patients, 6\u201312 months in 28% of the patients and \u226512 months in 10% of the patients (median 5, quartiles 2\u20138 months). Highest estimated benefit was observed in younger patients (aged 40\u201360 years) with high risk factor burden, particularly if LDL-C levels were &gt;1.8\u2009mmol\/L (&gt;70\u2009mg\/dL). Estimated benefit was lowest (\u22645 months) in older patients (\u226570 years), in particular if LDL-C and other risk factors levels were low.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The individual estimated lifetime benefit from PCSK9 inhibition in patients with stable CAD on high-dose statin varied from &lt;6\u2009to \u226512 months free of stroke or MI. Highest benefit is expected in younger patients (age 40\u201360 years) with high risk factor burden and relatively high LDL-C levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT00327691\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial post-results\">NCT00327691<\/jats:ext-link>; Post-results<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2017-312510","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T18:37:59Z","timestamp":1522953479000},"page":"1699-1705","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease"],"prefix":"10.1136","volume":"104","clinical-trial-number":[{"clinical-trial-number":"nct00327691","registry":"10.18810\/clinical-trials-gov","type":"postResults"}],"author":[{"given":"Lotte","family":"Kaasenbrood","sequence":"first","affiliation":[{"name":"Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Matthijs","family":"Boekholdt","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvo M","family":"Smulders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"LaRosa","sequence":"additional","affiliation":[{"name":"SUNY Health Science Center, Brooklyn, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J P","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A N","family":"Dorresteijn","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L J","family":"Visseren","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"key":"2025092006181445000_104.20.1699.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.088591"},{"key":"2025092006181445000_104.20.1699.2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"2025092006181445000_104.20.1699.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.10.824"},{"key":"2025092006181445000_104.20.1699.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664"},{"key":"2025092006181445000_104.20.1699.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv616"},{"key":"2025092006181445000_104.20.1699.6","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2957"},{"key":"2025092006181445000_104.20.1699.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"2025092006181445000_104.20.1699.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"2025092006181445000_104.20.1699.9","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-303640"},{"key":"2025092006181445000_104.20.1699.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2012.01.014"},{"key":"2025092006181445000_104.20.1699.11","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.116.306887"},{"key":"2025092006181445000_104.20.1699.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.022134"},{"key":"2025092006181445000_104.20.1699.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050461"},{"key":"2025092006181445000_104.20.1699.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2003.09.031"},{"key":"2025092006181445000_104.20.1699.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2006.01.014"},{"key":"2025092006181445000_104.20.1699.16","doi-asserted-by":"crossref","first-page":"ehv340","DOI":"10.1093\/eurheartj\/ehv340","article-title":"Cholesterol, not just cardiovascular risk, is important in deciding who should receive statin treatment","volume":"18","author":"Soran","year":"2015","journal-title":"Eur Heart J"},{"key":"2025092006181445000_104.20.1699.17","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11883-015-0499-4","article-title":"Targeting PCSK9 for therapeutic gains","volume":"17","author":"Shapiro","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"2025092006181445000_104.20.1699.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i1548"},{"key":"2025092006181445000_104.20.1699.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c6624"},{"key":"2025092006181445000_104.20.1699.20","doi-asserted-by":"crossref","unstructured":"Steyerberg EW . Clinical prediction models: a practical approach to development, validation, and updating. New York: Springer, 2009.","DOI":"10.1007\/978-0-387-77244-8"},{"key":"2025092006181445000_104.20.1699.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.02.016"},{"key":"2025092006181445000_104.20.1699.22","doi-asserted-by":"crossref","unstructured":"Kumbhani DJ , Steg PG , Cannon CP , et al . Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. Am J Med 2013:693\u2013700.doi:10.1016\/j.amjmed.2013.01.033","DOI":"10.1016\/j.amjmed.2013.01.033"},{"key":"2025092006181445000_104.20.1699.23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/jamacardio.2016.0991","article-title":"Risk of premature cardiovascular disease vs the number of premature cardiovascular events","volume":"1","author":"Sniderman","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2025092006181445000_104.20.1699.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001361","article-title":"Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study","volume":"9","author":"Ferket","year":"2012","journal-title":"PLoS Med"},{"key":"2025092006181445000_104.20.1699.25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M15-2129","article-title":"Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. preventive services task force","volume":"164","author":"Dehmer","year":"2016","journal-title":"Ann Intern Med"},{"key":"2025092006181445000_104.20.1699.26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/clc.22535","article-title":"Cost-Effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States","volume":"39","author":"Gandra","year":"2016","journal-title":"Clin Cardiol"},{"key":"2025092006181445000_104.20.1699.27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value","volume":"176","author":"Tice","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025092006181445000_104.20.1699.28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"2025092006181445000_104.20.1699.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021314"},{"key":"2025092006181445000_104.20.1699.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.018383"},{"key":"2025092006181445000_104.20.1699.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2017-312510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T13:18:26Z","timestamp":1758374306000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2017-312510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":31,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2018,9,27]]},"published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1136\/heartjnl-2017-312510"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2017-312510","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,5]]}}}